Afsaneh Zare1, Reza Fardid2,3, G Holam Hossein Tamadon4,5, Mohammad Amin Mosleh-Shirazi3,6. 1. Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. Email:rfardid@gmail.com. 3. Ionizing and Non-Ionizing Radiation Protection Research Centre, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Diagnostic Laboratory Sciences and Technology Research Centre, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 6. Physics Unit, Department of Radio-Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Breast cancer is a complicated disease with genetic
diversity that encompasses a wide range of changes in
structure and gene expression. Since breast cancer is very
prevalent and is the second cause of mortality amongst
women, further research is vital in this field (1).MicroRNAs (miRNAs) play important role in the
diagnosis and treatment of cancers (2). MiRNAs comprise
19-25 nucleotides and they play a role in the arrangement
of gene expressions. There are a few studies on radiation
and miRNAs (3). In addition, miRNAs play a major role
in several processes, such as apoptosis, differentiation,
cell migration, and proliferation (4). Recently, the number
of identified miRNAs in the process of gene arrangement
has significantly increased (3). In order to achieve their
intended target, miRNAs can play the role of tumour
suppressor or oncogene (5).MiRNAs can be potential candidates for breast cancer
biomarker and used for early prognosis and diagnosis (6).
MiR-155 increases in several cancers, including breast
cancer (7). Recently, the influence of evidence-based
miR-155 on suppressor of cytokine signalling 1 (SOCS1)
was found to play a role in tumour suppression. An
increase in miR-155 results in a decrease in SOCS1 levels
(8). In addition, in another study the impact of miR-155
on caspase3 was observed as a suppressor with a major
role in apoptosis (9).In a study of rat breast cancer epithelial cells, miR-155,
an inter-mediator in the TGFB pathway, was found to have
a central role in cell formation epithelial-mesenchymal
transition (EMT) and increased considerably (10). In
general, although miR-155 increases in breast cancer, in some research, a decrease in miR-155 in some hormonal
receptors has been seen (11). Increases in miR-21 have
been reported in some cancers, including breast cancer (12,
13). The increase in miR-21 in cancer cells was shown to
be specific when compared to normal breast cells (13). An
investigation of 199 breast cancer patient and 21 healthy
control by real-time polymerase chain reaction (qRT-PCR) showed a significant level of miR-21 (14). The
amount of miR-21 expression in grades 2 and 3 cancer
cells is higher than grade 1. MiR-21 is one of the major
regulators of miRNAs in different cell pathways; this
miRNA regulates metastasis and can control cell viability.
Tropomyosin-1 is an important growth-inhibiting protein
that is negatively regulated by miR-21 (15-17).Let-7a is part of the first known miRNAs, with a 12
member’s family (18). Let-7a regulates many targets in
cell pathways and the levels of these targets increase in
breast cancer. There is a negative feedback between let-7a
and lin-28 (19). Gene producer let-7a is on chromosome
13, a fragile part of the gene that is constantly being
deleted. Studies have shown that in undifferentiated
cells, let-7a is also absent and the chance of cancer is
also increased (20). The results of one study showed a
decrease in let-7a in breast cancer cells (BT-IC) and an
increase in let-7a in differentiated cells (21). Dingo and
colleagues reported a role for let-7a in breast cancer
metastasis by RKIP regulation. RKIP is a gene suppressor
in breast cancer cells (22). The changes in miRNA
expression profiles in response to irradiation have not
been comprehensively analyzed. The present study was
designed to assess potential changes that occur in miRNA
expression following irradiation.
Materials and Methods
This experimental research was designed to examine
the effect of ionizing radiation on expression changes in
three miRNAs - miR-155, miR-21, and let-7a. This study
was conducted at Shiraz University of Medical Sciences
with the support of the Vice Chancellor for Research
and was registered by the Ethics Committee (IR.SUMS.
REC.1397.538).
Cell culture
We obtained both human breast cancer cell lines (MCF-7) and human normal breast cell line
(MCF-10A) from Pasteur institute of Iran (Tehran, Iran). The cells were supplemented with
10% foetal bovine serum (FBS, Merck, Germany) and 1% penicillin-streptomycin (Merck,
Germany), and cultivated in 20 flasks in medium at 37˚C and 5% CO2 under
carefully controlled conditions. Each group was cultured in three flasks and twice testing
was performed for each flask.
Ionizing radiation treatment
The cultured cells were irradiated with different doses of ionizing radiation. The cells
received 50, 100, 400, 2000, and 4000 mGY administered by a linak accelerator (Elekta
Company, Sweden) at 6 mv and source-skin distance (SSD) of 100 cm and a dose rate of 200
mu/minutes. The experiments were conducted at Namazi Hospital, Shiraz, Iran. The
irradiated cells were maintained at 37˚C and 5% CO2 for six hours prior to
total RNA extraction conducted in accordance with the manufacturer’s instructions.
RNA extraction
Total RNA was extracted from the cultivated MCF-7
and MCF-10A cell lines using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) in accordance with the manufacturer’s
instructions. Both the RNA concentration and integrity were
quantified in each sample by a NanoDrop (Bioner, South
Korea) instrument before the samples were stored at -70˚C.
cDNA synthesis and real-time polymerase chain
reaction
cDNA synthesis was conducted with a KIT protocol
(Exiqon, Denmark) according to the manufacturer’s
instructions. An average of 2 µl of the total miRNAs
was used for cDNA synthesis based on the evaluation
of the NanoDrop instrument. For recognizing miRNAs
expression and RT-PCR, we used 10 ml of ROX and
SYBR-green (Exiqon, Denmark), 1 µl cDNA, 1 µl
primer, and 8 µl DEPC Water (DW) according to the
manufacturer’s instructions. In order to specify the
amount of miRNA expression and for RT-PCR analysis,
we used Oligo-dT primer to design specific primers for
miR-155, MiR-21, and let-7a. MiR-5s was purchased
from mentioned company (Exiqon, Denmark), for internal
control. The expression levels of these three miRNAs
were evaluated by an ABI Step One QPCR according
to the manufacturer’s instructions. Briefly, all samples
were incubated for 60 minutes at 42˚C, followed by heat
inactivation of the reverse transcriptase (RT-enzyme) at
95˚C for 5 minutes. Additionally, 5S rRNA gene was
used as an internal control. The RT-PCR reactions were
performed at 95˚C for 10 minutes, followed by 40 cycles
at 95˚C for 10 seconds, and 60˚C for one minute with an
ABI 7500 qRT-PCR system (Applied Biosystems, Foster
City, CA, USA).
Bioinformatics analysis
Identification of putative and validated target genes among
the differentially expressed genes for all the studied seven
miRNAs was performed by using Web-based software
analysis. The corresponding gene, miRBase ID, and
sequence of each miRNA in this study were assigned before
analysis. The Web-based software used to investigate the
miRNA targets were: miRTarBase (http://miRtarbase.mbc.
nctu.edu.tw), miRecords (http://miRecords.biolead.org/),
TargetScan (http://www.targetscan.org/), miRanda (http://
www.microrna.org), DIANA microT (http://diana.imis.
athena-innovation.gr/DianaTools), and miRwalk (http://zmf.
umm.uni-heidelberg.de/apps/zmf/miRwalk2/).
Statistical analysis
All experiments were performed in duplicate. Data were analysed by software used in an
ABI instrument by taking into consideration the obtained cycle threshold (CT) numbers and
the estimated melting curve using device for any miRNA in each irradiation. We had a CT
number which was normalized to internal control (miR-5s) by Graph Pad Prism 5.0 (Graph Pad
Software, Inc., La Jolla, CA, USA), finally use 2 (ΔΔ ct) were expressed as
log2 values.
Results
The MCF-7 and MCF-10A cell lines were cultivated
under appropriate conditions and subsequently irradiated
with varying doses (50, 100, 400, 2000, or 4000 mGY).
After six hours, we evaluated miRNA expression levels
by qRT-PCR. Irradiation from low to high doses showed
an increase in miR-155 expression in the cancer cell line
in comparison with normal cells, and this represented the
probability of breast cancer at the various doses. Down-regulation occurred between the 100 to 400 mGY doses,
which could be considered a reduction related to the
chance of breast cancer at the 400 mGY dose compared to
the lower doses. We observed up-regulation in the doses
after 400 mGY (Fig .1)
Fig.1
The relative expression of miR-155 in the MCF-10A and MCF-7 cell
lines after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA
(miRNA) expressions were assessed after six hours. There is a chance for
breast cancer in the low to high doses.
The relative expression of miR-155 in the MCF-10A and MCF-7 cell
lines after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA
(miRNA) expressions were assessed after six hours. There is a chance for
breast cancer in the low to high doses.MiR-21 expression was up-regulated and down-regulated in the cancer cells in comparison with the
normal cells. There was up-regulation in 50 and 100
mGY doses; hence, it could be said that the probability
of breast cancer increased in this dose due to the increase
in miR-21 expression in breast cancer. However, we had
a decrease in the expression of miR-21 in the cancer cells
compared to normal cells at the 200 mGY dose, followed
by an overlap to 4000 mGY. The minimum possibility to
develop cancer in miR-21 after irradiation was 400 mGY
where we had a significant difference between normal
cells and cancer cells (Fig .2).
Fig.2
Relative expression of miR-21 in the MCF-10A and MCF-7 cell lines
after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA (miRNA)
expressions were assessed after six hours. Up-regulation and down-regulation were observed at different doses.
The reduction in let-7a in cancer cells compared to
normal cells is a fact. Overally, we observed a decrease
in let-7a expression in cancer cells compared with normal
ones, which could be considered as an increased chance
for breast cancer in the low to high doses. There was
no significant increase or decrease in let-7a expression
in the low to high doses; however, the most significant
amount change to level of let-7a expression between
normal and cancer cells was observed at the 400 mGY
dose (Fig .3).
Fig.3
Relative expression of let-7a in the MCF-10A and MCF-7 cell lines
after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA (miRNA)
expression was assessed after six hours. There is a chance of breast cancer
in the low dose to high doses.
Relative expression of miR-21 in the MCF-10A and MCF-7 cell lines
after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA (miRNA)
expressions were assessed after six hours. Up-regulation and down-regulation were observed at different doses.Relative expression of let-7a in the MCF-10A and MCF-7 cell lines
after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA (miRNA)
expression was assessed after six hours. There is a chance of breast cancer
in the low dose to high doses.The MCF-7 cancer cell line was affected by let-7a
down-regulation and miR-155 and miR-21 up-regulation.
In terms of the irradiation effect, we observed a similarity
in expressions of miR-155 and miR-21 in the cancer cells
after irradiation. The higher probability of breast cancer
was observed at the 100 mGY dose and the minimum
probability was at the 400 mGY dose. For let-7a, the most
significant effect was observed with the least possible
expression, which occurred with the 400 mGY dose and
the least irradiation effect was at 4000 mGY, which had
the most expression (Fig .4).
Fig.4
Relative expressions of miR-155, miR-21, and let-7a in the MCF-7
cell line after irradiation at 50, 100, 400, 2000 and 4000 x-rays. MicroRNA
(miRNA) expression was assessed after six hours.
Relative expressions of miR-155, miR-21, and let-7a in the MCF-7
cell line after irradiation at 50, 100, 400, 2000 and 4000 x-rays. MicroRNA
(miRNA) expression was assessed after six hours.The changes in expressions of miR-155, miR-21 and
let-7a in the MCF-10A cell line (normal cells) are seen in
the form of increase and decrease on different doses. In
the case of let-7a, probability of breast cancer increased at
the 2000 mGY dose compared to the 4000 mGY dose, due
to a reduction in expression level. MiR-21 expression in
normal cells at different doses showed that the probability
of breast cancer has increased followed by a decrease at
2000 mGY compared to 400 mGY. MiR-155 expression
in normal cells had no significant decrease or increase;
however, it can be said that probability of breast cancer
after irradiation was high at the 400 mGY dose compared
to the other doses because we observed the highest
expression (Fig .5).
Fig.5
Relative expressions of miR-155, miR-21, and let-7a in the MCF-10A
cell line after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA
(miRNA) expression was assessed after six hours.
Relative expressions of miR-155, miR-21, and let-7a in the MCF-10A
cell line after irradiation at 50, 100, 400, 2000, and 4000 mGY. MicroRNA
(miRNA) expression was assessed after six hours.
Discussion
There are recent significant developments in the field
of molecular analysis and problem-solving aetiology.
MiRNAs are a new category of endogenous RNA
molecules that have aroused great interest in the scientific
community. MiRNAs are often expressed in cancer. A new
source of upstream molecular factors of gene expression
has been discovered, which warrants extensive research
to clarify their roles in cancer.We studied the association between miRNAs and breast
cancer. The role of miRNAs as an effective diagnostic
factor for breast cancer was the focus of our research.
MiRNAs have important roles in cancer diagnosis that are
very important like germ cell tumours (23). Although one
of the most important factors that influences the process
of cancer is radiation, there are few studies of irradiation
on miRNAs and breast cancer. A recent study showed the
effect of different radiation doses on two types of cancer
cell lines through the miRNA pathway (24). miRNAs are
also used to treat breast cancer (25).A double strand break (DSB) is a fatal damage caused
by ionizing radiation that should be restored; one of
the major components in this restoration is RAD51.Gasparini et al. (26) reported that the increase in miR-155 in breast cancer cells would lead to a reduction
in RAD51 levels and would affect the cell response to
radiation. Consequently, along with radiation and an
increase in miR-155 and consequent decrease in RAD51,
cell sensitivity to radiation will increase. The results of
the present study indicated increased miR-155 expression
in the normal cell line compared to the cancer cell line,
which could increase radio-sensitivity and the chance of
breast cancer. Although in different doses we observed
an increase and decrease. An important finding of miR-155 is the relationship with BRCA1. Chang et al. (27)
showed that BRCA1 play an important role in damage to
DNA repair and cell cycle. The function of BRCA1 will
decrease with cell mutations and increases in miR-155.
Based on the results of our research, an increase in
miR-155 expression and a decrease in the performance
of BRCA1 can lead to an increased chance for breast
cancer.One direct target of miR-21 is CDC25a, which has a tremendous effect on cell repair and
increase of checkpoint arrest (28, 29). Also, miR-21 can be use as a radio-resistance,
since, with increasing radiation dose and the need for DNA repair, an increase in miR-21 and
CDC25a has been observed and this result can be seen in the 100 mGY dose. Although miR-21 is
observed in breast cancer, there is no clear pattern of gene target of this miRNA, like
PTEN; therefore, additional investigation is necessary (15) .Let-7a has a key role in proliferation, differentiation
and tumour suppression (30). There are contradictory
results regarding increases or decreases in let-7a
after radiation. The results of a study on lung cancer
indicated down-regulation of let-7a. There was up-regulation in the entire let-7a family in a glioma cell
line (31). In addition, the p53 path in determining
the amount of let-7a expression is interesting after radiation. In a study after ionizing radiation (IR), we
observed down-regulation of let-7a in cells sensitive
to radiation, such as the lungs and bone marrow, while
there was up-regulation in let-7a in cells resistant to
radiation, like the brain and muscles (32). This change
could come from several factors, including the type
and amount of radiation and paths involved in let-7a
regulations (e.g., line 28 and RAS) (33). We observed
a significant decrease in let-7a in the cancer cells
compared to the normal cells; hence, it can be inferred
that there was a chance of breast cancer from the low
dose to the high dose of irradiation.
Conclusion
According to the results from various studied that
investigated the relationship between miRNAs and
radiation, we concluded that irradiation affects breast
and other cancers. Our findings showed up-regulation
of miR-155 and let-7a with an increase in irradiation
dose. It could be said that the probability of breast
cancer increases following irradiation in normal and
cancer cells. However, we did not see miR-21 up-regulation with increased irradiation. We observed
up-regulation and down-regulation at different doses.
We could not say that the probability of breast cancer
increased after irradiation in miR-21. The current
and previous research studies could be a promising
approach for the effect of radiation on miRNA
expression. The role of miRNAs in breast cancer is
suggested in diagnostic radiology and radiotherapy
and in radiation accidents.
Authors: Sam Mattiske; Rachel J Suetani; Paul M Neilsen; David F Callen Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Suzanne Hagan; Fahd Al-Mulla; Elizabeth Mallon; Karin Oien; Rhona Ferrier; Barry Gusterson; Jorge J Curto García; Walter Kolch Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Klaus-Peter Dieckmann; Arlo Radtke; Lajos Geczi; Cord Matthies; Petra Anheuser; Ulrike Eckardt; Jörg Sommer; Friedemann Zengerling; Emanuela Trenti; Renate Pichler; Hanjo Belz; Stefan Zastrow; Alexander Winter; Sebastian Melchior; Johannes Hammel; Jennifer Kranz; Marius Bolten; Susanne Krege; Björn Haben; Wolfgang Loidl; Christian Guido Ruf; Julia Heinzelbecker; Axel Heidenreich; Jann Frederik Cremers; Christoph Oing; Thomas Hermanns; Christian Daniel Fankhauser; Silke Gillessen; Hermann Reichegger; Richard Cathomas; Martin Pichler; Marcus Hentrich; Klaus Eredics; Anja Lorch; Christian Wülfing; Sven Peine; Werner Wosniok; Carsten Bokemeyer; Gazanfer Belge Journal: J Clin Oncol Date: 2019-03-15 Impact factor: 44.544